Depression of C fiber-evoked activity by intrathecally administered reactive red 2 in rat thalamic neurons.
To investigate the possible role of spinal purinoceptors in nociception, the potent P2-purinoceptor antagonist reactive red 2 was studied in rats under urethane anesthesia in which nociceptive activity was elicited by electrical stimulation of afferent C fibers in the sural nerve and recorded from single neurons in the ventrobasal complex of the thalamus. Intrathecal (i.t.) application of reactive red 2 (6-200 micrograms) caused a dose-dependent reduction of the evoked activity in thalamic neurons. The estimated ED50 was 30 micrograms, and the maximum depression of nociceptive activity amounted to about 70% of the control activity at a dose of 100 micrograms. Morphine, administered i.t. at a maximally effective dose (80 micrograms), inhibited the evoked nociceptive activity by only up to 55% of the control activity. An i.t. co-injection of reactive red 2 (100 micrograms) and morphine (80 micrograms) caused a maximum reduction of the evoked thalamic activity by up to 85% of the control activity, thus, exceeding significantly the effect elicited by either drug alone. Similarly, i.t. co-injection of almost equipotent dosages of reactive red 2 (30 micrograms) and morphine (30 micrograms) caused a maximum reduction of the evoked activity by up to 72% of the control activity, which again exceeded significantly the effect of either drug alone. The results suggest that in rats reactive red 2 exerts antinociception by blockade of P2-purinoceptors in the spinal cord and, hence, support the idea that ATP may play an important role in spinal transmission of nociceptive signals. An activation of the spinal opioid system does not seem to contribute to the effect of reactive red 2 but might act additive or even synergistically with its antinociceptive action.
University of California, Veterinary Medical Teaching Hospital, Davis 95616, USA. bbdriessen@ucdavis.edu
B
B
Driessen
R
R
Bültmann
I
I
Jurna
J
J
Baldauf
D000818:Animals; D004396:Coloring Agents / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D005260:Female; D007278:Injections, Spinal; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009282:Naphthalenesulfonates / Q000008:administration & dosage* / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology; D009412:Nerve Fibers / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology; D058914:Purinergic Antagonists; D051381:Rats; D017208:Rats, Wistar; D011983:Receptors, Purinergic / Q000502:physiology; D013116:Spinal Cord / Q000378:metabolism / Q000502:physiology; D013497:Sural Nerve / Q000187:drug effects / Q000502:physiology; D013788:Thalamus / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D014227:Triazines / Q000008:administration & dosage* / Q000494:pharmacology
D004396:Coloring Agents; D009282:Naphthalenesulfonates; D009294:Narcotics; D058914:Purinergic Antagonists; D011983:Receptors, Purinergic; D014227:Triazines; C098610:reactive red 2; D009020:Morphine